Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juli 2017

Planlagt Fastgjort Låst Flyttet Genmab
985 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    Jedi
    wrote on sidst redigeret af
    #91

    I agree. The current problems of Keytruda are limited to MM. All Keytruda trials outside MM continue at full speed and PD-1 / PD-L1 agents are still considered very successful in solid tumors

    1 Reply Last reply
    0
    • J Offline
      J Offline
      Jedi
      wrote on sidst redigeret af
      #92

      The new Celgene collaboration on PD-1 is also targeting solid tumors and not MM

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #93

        Ingen tvivl om at PD-1 kører ufortrødent videre i solide tumorer. Så må vi vente og se om Opdivo (sammen med dara) giver problemer i MM.

        1 Reply Last reply
        0
        • J Offline
          J Offline
          Jedi
          wrote on sidst redigeret af
          #94

          Det kunne jo også være kombinationen af PD-1 og en Imid (Revlimid/Pomalyst) som giver en uheldig bivirkning i MM, mens Dara + PD-1 virker ok, det kan vi håbe på - det bliver spændende at følge

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #95

            NICE : Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Technology appraisal [TA454] Published date: 05 July 2017
            https://www.nice.org.uk/guidance/ta454

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #96

              this is as expected, Janssen had withdrawn this application

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #97

                we wati for this Daratumumab for multiple myeloma [ID933] In development [GID-TA10076] Expected publication date: 26 July 2017

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #98

                  but there is a negative advice for that one as we know, so small chance only that they´ll approve

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #99

                    you have to love this italian title - daratumumab, "killer seriale"
                    lol https://www.pharmastar.it/news/italia/mieloma-multiplo-disponibile-anche-in-italia-daratumumab-killer-seriale-delle-cellule-tumorali--24458

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      JKY_VH
                      wrote on sidst redigeret af
                      #100

                      🙂

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bibob
                        wrote on sidst redigeret af
                        #101

                        God morgen. 🙂

                        1 Reply Last reply
                        0
                        • DarvinD Offline
                          DarvinD Offline
                          Darvin
                          wrote on sidst redigeret af
                          #102

                          Morgen. Dejligt igen i dag at se opdateringer på hele 4 studier bl. A https://clinicaltrials.gov/ct2/show/NCT02609776?term=Genmab+OR+Daratumumab+OR+Darzalex+OR+JNJ-63709178+OR+JNJ-61186372+OR+AMG+714+OR+Teprotumumab+OR+Tisotumab+OR+OFATUMUMAB+OR+JNJ-64007957+OR+TF-adc+OR+Humax-Axl-adc&lup_s=07%2F01%2F2017&rank=3 JNJ-61186372. På et tidspunkt - længere fremme vil vi være i en situation, hvor vi hver måned får serveret 1 eller flere resultater på studier. Med alle de som er i gang

                          1 Reply Last reply
                          0
                          • bongobobB Offline
                            bongobobB Offline
                            bongobob
                            wrote on sidst redigeret af
                            #103

                            Det er gode tegn. x372 er den Duobody der er udviklet af Genmab. forsøget er udvidet fra 40 til 90 patienter

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #104

                              Ja og royalty lige en tand højere end de øvrige

                              1 Reply Last reply
                              0
                              • bongobobB Offline
                                bongobobB Offline
                                bongobob
                                wrote on sidst redigeret af
                                #105

                                NSCLC må være en stor indikation. Nå men nu skal vi lige se data først. Nu har den kørt i noget der ligner 18 md. Måske kan de fremlægge data og ændre det til et phase 1/2 hvis det ser godt ud

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #106

                                  God morgen. 🙂

                                  1 Reply Last reply
                                  0
                                  • B Offline
                                    B Offline
                                    BobTheThird
                                    wrote on sidst redigeret af
                                    #107

                                    Uf, små hård start på dagen..

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #108

                                      Hvordan det?

                                      1 Reply Last reply
                                      0
                                      • A Offline
                                        A Offline
                                        AaBforever
                                        wrote on sidst redigeret af
                                        #109

                                        Jeg tror han mente kursen, Helge

                                        1 Reply Last reply
                                        0
                                        • A Offline
                                          A Offline
                                          AaBforever
                                          wrote on sidst redigeret af
                                          #110

                                          Jeg har forleden doneret et beløb via MobilePay. Har du modtaget beløbet?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger